Iambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage development pipeline, announcing 3 October that it closed a $100m series B round. The company formerly known as Entos Inc. follows many peers with AI-powered discovery and development platforms that have raised big money in 2023.
San Diego-based Iambic – not to be confused with Entos Pharmaceuticals, Inc., a UK-based company that also has operations...






